You, H., Yan, Z., Zhai, Y., Yao, W., Yan, S., Shi, X., Shang, J., Jin, S., Yan, L., Wu, D., Fu, C. (2025). Treatment of high-risk newly diagnosed multiple myeloma with minimal residual disease-guided therapy:daratumumab, carfilzomib, lenalidomide, and dexamethasone (DKRd). Blood. https://doi.org/10.1182/blood-2025-5782